Intra-Cellular Therapies, Inc.

ITCI04 Dec 2024
Healthcare
$85.62
+0.01 (+0.66%)
Lowest Today
$84.89
Highest Today
$85.93
Today’s Open
$85.62
Prev. Close
$85.31
52 Week High
$93.45
52 Week Low
$58.93
To Invest in Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc.

Healthcare
ITCI04 Dec 2024
+0.01 (+0.66%)
1M
3M
6M
1Y
5Y
Low
$84.88
Day’s Range
High
$85.93
84.88
52 Week Low
$58.92
52-Week Range
52 Week High
$93.45
58.92
1 Day
-
1 Week
-1.55%
1 month return
-1.06%
3 month return
+17.28%
6 month return
+25.57%
1 Year return
+38.85%
3 Years return
+142.39%
5 Years return
+755.56%
10 Years return
-
Institutional Holdings
FMR Inc
10.49
Vanguard Group Inc
9.08
BlackRock Inc
5.96
JPMorgan Chase & Co
4.99
Fidelity Growth Compy Commingled Pl S
3.67
Wasatch Advisors LP
3.63
Vanguard Total Stock Mkt Idx Inv
3.02

Market Status

Fundamentals
Market Cap
9120.64 mln
PB Ratio
7.97
PE Ratio
0
Enterprise Value
8131.8 mln
Total Assets
728.3 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Organisation
Intra-Cellular Therapies, Inc.
Employees
610
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Sharon  Mates Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step